CORCEPT THERAPEUTICS INC
For the period ended Dec 31, 2025. Filed Feb 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 24, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Insider Trading Arrangements
During the quarter ended December 31, 2025, none of directors and officers (as defined in Rule 16a-1(f) under the Exchange Act)adopted orterminated any contract, instruction or written plan for the purchase or sales of our securities that are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, or any “non-Rule 10b5-1 trading arrangement,” as defined in Item 408(a) of Regulation S-K, other than as set forth in the table below.
| Name | Position | Action | Adoption Date | Total Shares of Common Stock to be Sold | Expiration Date(1) |
|---|---|---|---|---|---|
| Sean Maduck | President, Corcept Endocrinology | Adoption | 12/8/2025 | Up to 600,000 | 6/30/2027 |
| Atabak Mokari | Chief Financial Officer | Adoption | 12/12/2025 | Up to 200,000 | 3/14/2027 |
(1) Each trading arrangement permits transactions through and including the earlier to occur of (a) the completion of all sales or (b) the date listed in the table.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.